Rheumatoid arthritis

Treatment.

An autovaccination-based technology is aimed to stimulate patient’s immune reactions directed selectively against pathogenic, self-reactive Т lymphocytes responsible for developing rheumatoid arthritis. Since autovaccinotherapy triggers the mechanism of the immune memory, its influence on the patient’s immune system is time-continuous and of long duration.

The preparation of a T-cell vaccine takes 10-to-14 days. The inductive course of the treatment consists of 4 weekly subcutaneous immunizations. For consolidating a vaccine effect, the immunizations are further fulfilled monthly. The treatment is conducted on an outpatient basis.

Infectious safety.

A vaccine is prepared from patient’s lymphocytes under conditions excluding their contamination with infectious agents.

Side effects.

No complications are described.

Clinical effect

Immune-mediated inactivation of pathogenic T lymphocytes provide the inhibition of articulation-deforming, inflammatory processes.

AUTOVACCINATION FOR RHEUMATOID ARTHRITIS

AUTOVACCINATION FOR RHEUMATOID ARTHRITIS

Rheumatoid arthritis is a disease due to the autoimmune process destructing a articular cartilage. A pivotal role for this process belongs to the proinflammatory T lymphocytes that are reactive to cartilage-associated antigens. The standard treatment of rheumatoid arthritis is based on applying medicines (hormones, cytostatic agents and others) with a non-specific (non-selective) immunosuppressive action. Such treatment fails to interrupt entirely the immunopatological events underlying the disease and is frequently associated with serious complications.

The autovaccination-based technology developed in our Centre exploits natural immunoregulatory mechanisms and is aimed to stimulate patient’s immune reactions directed selectively against pathogenic, self-reactive Т lymphocytes.

The Т cell vaccination technology involves two successive stages:

  1. Preparation of self-reactive Т cells by culturing patient’s blood lymphocytes in vitro (out of the body) in the presence of cartilage-associated antigens.

  2. Vaccinotherapy of the patient with the prepared T lymphocytes.

The immune-mediated, selective inactivation of the self-reactive T- lymphocytes may results in inhibiting disease development. Since autovaccinotherapy triggers the nature-based mechanism of the immune memory, its influence on the patient’s immune system may be time-continuous and of long duration.

Clinical improvements are noted in the most l vaccine-treated patients. Noteworthy is that the benefits from autovaccinotherapy may be observed in the patients not only at the early, but also at late stages of the disease. They may develop as early as during 1-to-2 months after treatment initiation. Autovaccination is safe and well tolerated; no complications were noted.

For more information see the publications .

back to the top